# A Study of Ruxolitinib for Preventing Graft-Versus-Host Disease in People With a Hematologic Malignancy Who Will Receive a Stem Cell Transplant

> **NCT07359859** · PHASE2 · RECRUITING · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 40 (estimated)

## Conditions studied

- Hematologic Malignancies

## Interventions

- **DRUG:** Cyclophosphamide
- **DRUG:** Cyclophosphamide
- **DRUG:** Mycophenolate Mofetil
- **DRUG:** Ruxolitinib
- **DRUG:** Tacrolimus
- **DRUG:** Tacrolimus

## Key facts

- **NCT ID:** NCT07359859
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-20
- **Primary completion:** 2029-01
- **Final completion:** 2029-01
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-02-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07359859

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07359859, "A Study of Ruxolitinib for Preventing Graft-Versus-Host Disease in People With a Hematologic Malignancy Who Will Receive a Stem Cell Transplant". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07359859. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*